Rubius Therapeutics brings in new CEO

pharmafile | June 11, 2018 | News story | Medical Communications, Sales and Marketing Rubius Therapeutics, biotech, drugs, pharma, pharmaceutical 

Rubius Therapeutics, a biotech that has ambitions to bring “super blood” to the market, has revealed that it has appointed a new CEO to lead the company.

Pablo Cagnoni enters the position, joining the biotech from Tizona Therapeutics, which he led as CEO. He joins the company not long after its second successful financing round, after the company raised $100 million in March.

The aim is to use the money to take its treatments through to the clinic. The class of medicine it is developing is unusual enough to gain serious investor interest – it involves developing red blood cells that are engineered to include specific proteins within or on the red cell.

The biotech aims to use this technology to treat a variety cancers and rare diseases, as well as helping regulate the immune system to combat autoimmune disorders.

Cagnoni arrives well-placed to aid in the development of cancer treatment, after having a spell with immuno-oncology-focused, Onyx Pharmaceuticals, as head of R&D.

“I am honoured to join Rubius as CEO to continue building the company’s broad and diverse pipeline of Red Cell Therapeutics in multiple therapeutic areas, while making a significant impact for patients with serious diseases,” said Dr. Cagnoni. “I look forward to partnering with Torben and the entire team.”

Torben Straight Nissen was formerly CEO but stepped down to the role of President, due to the appointment of Cagnoni.

Explaining the decision to appoint Cagnoni, David Epstein, Chairman of Rubius Therapeutics, said: “Pablo’s deep industry expertise and role in the development and commercialization of more than 20 life-changing treatments positions him to lead Rubius as we continue to advance a new class of medicines to treat cancer, autoimmune diseases and rare diseases. We are extremely pleased to welcome Pablo as CEO.”

Ben Hargreaves

Related Content

Pfizer sign

Delayed Pfizer vaccine dose gives 3.5 times more immunity, study shows

The Pfizer-BioNTech COVID-19 vaccine is around three and a half times more effective when dosed …

Amgen flag

AstraZeneca and Amgen asthma drug shows positive results in Phase III trial

AstraZeneca and Amgen’s new tezepelumab drug for the treatment of severe asthma has shown superiority …

India report record number of COVID deaths as bodies drift down Ganges

India yesterday reported the country’s highest COVID-19 death total for a single day, with 4,205 …

Latest content